Ali Max Erturk

Ertürk earned a bachelor’s degree from Bilkent University in 2003 and a doctorate from LMU Munich in 2009.⁠[1]

In 2009, he moved to Genentech in South San Francisco for postdoctoral research.⁠[2]

A 3DISCO protocol for three-dimensional organ imaging, coauthored by Ertürk, appeared online on October 11, 2012, in Nature Protocols’ November issue.⁠[3]

He coauthored the uDISCO study, which combined tissue clearing and shrinkage to image nerves and vessels across intact rodents.⁠[4]

His university CV dates the start of his directorship of Helmholtz Munich’s Institute for Tissue Engineering and Regenerative Medicine to July 2019.⁠[5]

DeepMACT combined tissue clearing, light-sheet microscopy and deep learning to detect micrometastases throughout mice and assess therapeutic-antibody targeting. Ertürk coauthored the work.⁠[6]

A team involving Ertürk introduced SHANEL to clear postmortem human organs for cellular-resolution three-dimensional imaging. Using these maps for future bioprinting remained a research goal.⁠[7]

LMU’s Faculty of Medicine lists Ertürk as a 2020 ERC Consolidator Grant recipient for CALVARIA, concerning translational aspects of skull-marrow–meninges connections.⁠[8]

His university CV lists him as Deep Piction’s founder and CEO from February, an LMU W3 professor from July, and a founder of 1X1 Biotech from September.⁠[5]

Deep Piction’s website identifies him as founder and CEO and describes combining whole-mouse imaging, AI and nanocarrier delivery for drug development.⁠[9]

Ertürk’s and Matthias Mann’s teams developed DISCO-MS, combining tissue clearing, robotic sampling and mass spectrometry to analyze regions located through three-dimensional imaging.⁠[10]

His team helped develop wildDISCO, using standard antibodies, clearing and light-sheet microscopy to map cellular structures across mice and share online atlases with researchers.⁠[11]

In September 2024, Helmholtz Munich announced that Ertürk had won that year’s Falling Walls Life Sciences award for integrating tissue clearing and AI.⁠[12]

In the organizer’s interview, he described a long-term goal of reducing animal experiments through digital simulations of biological systems.⁠[13]

SCP-Nano research by Ertürk and collaborators combined clearing, light-sheet imaging and deep learning to track nanocarrier distribution throughout mice at single-cell resolution.⁠[14]

His team published MouseMapper, a deep-learning framework for whole-mouse nerve and immune-cell analysis, studying obesity-associated changes and finding some corresponding molecular signatures in human tissue.⁠[15]

Ertürk Lab: Official website: https://www.erturk-lab.com/team/ali-maximilian-erturk/ (opens in a new window)⁠[1]

Helmholtz Munich profile: Official website: https://www.helmholtz-munich.de/en/bioengineering-center/ibio/ali-ertuerk (opens in a new window)⁠[2]

Deep Piction: Official website: https://www.deeppiction.com/ (opens in a new window)⁠[9]

Bilkent University: Official website: https://w3.bilkent.edu.tr/bilkent/ (opens in a new window)⁠[16]

LMU Munich: Official website: https://www.lmu.de/en/ (opens in a new window)⁠[17]

Genentech: Official website: https://www.gene.com/ (opens in a new window)⁠[18]

Ali Max Erturk on X: Official account: https://x.com/erturklab (opens in a new window)⁠[19]

Ali Maximilian Ertürk on LinkedInLinkedInLinkedIn is a social networking platform for professionals. It was founded in 2002 by Reid Hoffman and others, launched in 2003, and listed on the New York Stock Exchange in 2011; after Microsoft acquired it for approximately $26.2 billion in 2016, it became a wholly owned Microsoft subsidiary. Its revenue comes from membership subscriptions, advertising, and recruitment solutions.Open the full entry: Official account: https://www.linkedin.com/in/ali-maximilian-ert%C3%BCrk/ (opens in a new window)⁠[20]